SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is currently a focal point for investors eyeing the intersection of autonomous AI agents and Web3 infrastructure, bolstered by recent partnerships and the development of the ASI:Chain. Community members are actively debating the token's long-term utility versus its speculative nature, often highlighting its accumulation potential during market fluctuations as they track ongoing developments in the decentralized AI landscape.

Chip

Chip is currently trending as a prominent AI infrastructure play, with the community actively debating its potential as a GPU-backed lending protocol versus concerns over volatility and insider selling. Investors are closely monitoring its performance as they weigh the project's real-world use case in financing AI hardware against the risks typical of early-stage, high-beta crypto assets.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

RE is trending as investors rally behind its emergence as a governance token for the decentralized reinsurance market, driving significant community excitement following recent listings on major trading platforms. The conversation is heavily focused on its real-world utility in insurance and the potential for a sustained price run, with many participants actively discussing buy-in strategies and long-term holding prospects.

Dogelon Mars

Dogelon Mars is seeing sustained community engagement and frequent trending status on social platforms as investors debate its potential for a massive breakout during current market volatility. The community remains divided, with some highlighting the risks of long-term stagnation while others push for continued accumulation, betting on future project developments and broader sector trends.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending as community members weigh its potential as a meme coin leader amidst broader crypto market volatility. While some investors remain optimistic about a sustained rally, others are actively debating whether meme tokens have entered a long-term decline or remain viable short-term opportunities.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is experiencing heightened market attention ahead of upcoming quarterly earnings as investors monitor the competitive landscape in its core HIV business and progress within its oncology portfolio. The community remains focused on recent acquisition-related activity and the company's ability to maintain its market dominance through new product pipeline developments.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley is trending as investors digest the bank's role as a major underwriter for the highly anticipated SpaceX IPO and ongoing developments regarding the firm's expanding digital asset strategy, including crypto ETF filings. The community remains focused on the bank's strong institutional pipeline, its wealth management performance, and broader market impacts following the recent wave of IPO advisory activity.

Conagra Brands, Inc. engages in the manufacture and sale of processed and packaged foods. It operates through the following segments: Grocery and Snacks, Refrigerated and Frozen, International, and Foodservice. The Grocery and Snacks segment includes branded, and shelf stable food products sold in various retail channels in the United States. The Refrigerated and Frozen segment is composed of branded, and temperature-controlled food products sold in various retail channels in the United States. The International segment offers branded food products in various temperature states, sold in various retail and foodservice channels outside of the United States. The Foodservice segment focuses on branded and customized food products, including meals, entrees, sauces, and a variety of custom-manufactured culinary products packaged for sale to restaurants and other foodservice establishments in the United States. The company was founded by Alva Kinney and Frank Little in 1919 and is headquartered in Chicago, IL.

Conagra Brands Inc

Conagra Brands is experiencing significant market pressure, highlighted by shares sliding to multi-year lows following the announcement of a CEO transition. Investors are actively debating whether this represents a generational value opportunity or a precursor to a potential dividend cut, even as insider buying signals growing confidence among the board.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending as investors monitor competitive landscape developments in the IgA Nephropathy market ahead of the upcoming mid-year clinical data readouts. The community is actively debating the differentiation of its dual BAFF/APRIL inhibitor, atacicept, against rival therapies while evaluating the stock's potential as a buyout candidate.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is generating significant community buzz following its inclusion in a massive multi-billion dollar missile defense contract, sparking optimism about its long-term potential in sovereign space defense. Investors are actively discussing the stock's transition toward high-margin data analytics and a path to profitability, though sentiment remains tempered by ongoing debates regarding the company's management and past volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Where Will TransMedics Group Stock Be in 10 Years?

Where Will TransMedics Group Stock Be in 10 Years...

TMDX Stock Rallies As Analyst Sees 77% Upside  — Here’s Why  

Equity

TD Cowen maintained its ‘Buy’ rating on TransMedics with a $120 price target. 


Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

TransMedics (NASDAQ: TMDX) has been hit hard as investors question margins, spending, and execution. But beneath the sell-off, the company's Organ Care System, aviation network, and National OCS Program could be building a deeper transplant infrastructure moat than the market rea...

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire ANDOVER, Mass., May 21, 2026 ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a...

TransMedics to Present at the William Blair 46th Annual Growth Stock Conference

TransMedics to Present at the William Blair 46th Annual Growth Stock Conference TransMedics to Present at the William Blair 46th Annual Growth Stock Conference PR Newswire ANDOVER, Mass., May 19...

TransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group dropped their target price on TransMedics Group from $152.00 to $124.00 and set a 'buy' rating on the stock in a research report on Wednesday...

TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD Cowen

TD Cowen reduced their target price on shares of TransMedics Group from $190.00 to $120.00 and set a "buy" rating for the company in a report on Wednesday...

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

Bearish Sentiment

Buying - this is temporary noise

Holding existing position

Selling / Trimming / Shorting

Watching from the sidelines

$TMDX is sliding after Stifel flagged a surge in "dry runs.". TransMedics investors are divided: is this a temporary operational blip or a structural crack in the growth story? Cast your vote below.

$TMDX sliding on &quot;dry run&quot; concerns - are you buying this dip?

Stocktwits

 sliding on "dry run" concerns - are you buying this dip?

Feed

News

Sentiment

Earnings

Fundamentals

Info

TMDXTransmedics Group Inc

Fundamentals

Latest TMDX News